NCT00671853View on ClinicalTrials.gov

Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Bipolar DisorderAnxietyAnxiety DisordersSubstance Use Disorders
Interventions
DRUG

Quetiapine XR

Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day

DRUG

Placebo for quetiapine XR

Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day

Trial Locations (1)

44106

University Hospitals Cleveland Medical Center, Cleveland

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

University Hospitals Cleveland Medical Center

OTHER